Background In vitro and in vivo studies have demonstrated both anticoagulant and antiproliferative effects of heparin. The purpose of this study was to assess the effect of local intramural delivery of heparin, using heparin-coated hydrogel balloons, on platelet deposition and early smooth muscle cell proliferation after in vivo balloon angioplasty.
The purpose of this study was to assess the effect of local intramural delivery of heparin, using heparin-coated hydrogel balloons, on platelet deposition and early smooth muscle cell proliferation after in vivo balloon angioplasty.
Methods and Results The effects of local heparin delivery were assessed during balloon angioplasty of porcine peripheral arteries. All balloon dilatations were performed with oversized hydrogel balloons coated with a known quantity of heparin. Balloon dilatations in contralateral vessels with uncoated hydrogel balloons served as study controls. The pharmacokinetics of heparin delivery were assessed using 3H-heparin to quantitate heparin wash-off from the balloon surface, heparin delivery to the arterial wall, and intramural persistence of drug. Platelet deposition at 1 hour after balloon injury was quantified using`'In-labeled platelets. Smooth muscle cell proliferation was assessed 6 to 7 days after angioplasty with immunohistochemical staining for proliferating cell nuclear A cute vascular closure and late restenosis are two major problems that continue to confront interventional cardiology. In part, mechanical factors such as vascular dissection and vessel recoil play a role in causing these suboptimal angioplasty results. Newer adjunctive angioplasty techniques, including intracoronary stents, coronary atherectomy, and laser angioplasty, have been developed to minimize these mechanical problems. Equally important, however, biological factors such as intracoronary thrombus formation and smooth muscle cell hyperplasia can lead to abrupt closure and to restenosis, respectively. To date, neither mechanical devices nor systemic pharmacological therapy has been completely effective in combating these problems.
Localized intramural delivery of therapeutic agents during balloon angioplasty has been proposed as a potential treatment for abrupt closure and for the prevention of chronic restenosis.1-10 Localized drug delivery theoretically is advantageous because it produces high intramural concentrations of a therapeutic agent at the angioplasty site while minimizing circulating drug levels that may cause undesirable systemic side effects. Prior attempts to deliver drugs intramurally have involved the use of various techniques including perforated balloon catheters, double-balloon catheters, polymeric-coated stents, iontophoresis, and periadventitial drug delivery.
A novel catheter-based drug delivery system that has been developed recently involves the use of hydrogelcoated balloons.7-'0 This system uses a standard polyethylene angioplasty balloon coated with a hydrogel polymer into which various drugs can be absorbed. Balloon inflation results in polymer contact with the vessel wall and diffusion of a given drug from the hydrogel polymer into the vessel wall. Previous work from our laboratory has documented the efficacy of this system in locally delivering the marker agent horseradish peroxidase7 and fluoresceinated heparin.8
The purpose of the present study was to assess the effects of local heparin delivery during in vivo balloon angioplasty of normal porcine peripheral arteries with heparin-coated hydrogel balloons. Specifically, the study was designed with three goals: first, to evaluate the pharmacokinetics of heparin-coated hydrogel balloons in terms of the quantity of heparin delivered and its intramural persistence; second, to assess the effect of locally delivered heparin on platelet deposition after balloon angioplasty; and third, to assess the effect of locally delivered heparin on early smooth muscle cell proliferation after balloon angioplasty.
Methods

Equipment
The drug delivery balloon system that was used in this study consists of a standard 4-cm polyethylene balloon angioplasty catheter coated with hydrogel (Hydro-Plus, Boston Scientific). The hydrogel consists of a network of cross-linked polyacrylic acid chains that are adherent to the balloon surface. Upon exposure to aqueous solution, water is absorbed into the hydrophilic hydrogel lattice structure, the hydrogel swells, and any drugs in solution are also absorbed into the matrix. The thickness of the coating ranges from 5 jam when dry to 25 um when fully saturated with water. At the time of angioplasty, the hydrogel is compressed against the vessel wall, expressing any agents from the hydrogel into the vessel wall.
Loading of Heparin onto Hydrogel-Coated Balloons
Hydrogel balloons ranging in size between 6 and 8 mm were coated with a known quantity of porcine intestinal mucosal heparin (Elkins-Sinn, Inc). For each balloon, heparin was pipetted onto the inflated balloon surface in 25-,uL aliquots.
The inflated balloon was then suspended in air and allowed to dry. This process was repeated until the total required volume was loaded.
For evaluation of effects on platelet deposition and smooth muscle cell proliferation, 3000 U of heparin was loaded onto each balloon in a total volume of 300 ,uL of heparin at a concentration of 10 000 U/mL. For pharmacokinetic studies, 3H-heparin (New England Nuclear) was obtained with an initial specific activity of 320 U/mCi and diluted as necessary with heparin (10 000 U/mL) before balloon loading. Amounts of 3H-heparin loaded on the balloon surface ranged between 0.01 and 75 ,uCi (1000 U heparin). Control balloons consisted of hydrogel-coated balloons dipped in saline.
Angioplasty Drug Delivery Protocol
Angioplasty with heparin-coated or control, saline-coated hydrogel balloons was performed on the iliac and carotid arteries of 25 anesthetized, 3-to-4-month-old (20 to Persistence of heparin on the hydrogel balloon surface in the intact circulation was evaluated in two pigs using 40 hydrogel balloons (7-mm diameter) coated with 1000 U of 3H-heparin. After heparin loading, balloons were inserted through a 9F introducer sheath into the blood stream for time periods ranging between 1 and 120 seconds. Balloons were then removed, excised from their shaft, and immersed in Solvable (New England Nuclear) for 12 hours. Fifteen milliliters of Aquasol (New England Nuclear) then was added, and after incubation for 12 hours, specimens were counted in a scintillation counter and reported as decays per minute (dpm) after subtraction of background counts. Four balloons coated with 3H-heparin were evaluated at each of the times listed in Table 1 . Three additional balloons enclosed in a protective 7F introducer sheath (USCI) were inserted through the 9F sheath and maintained within the circulation for 5 minutes. After removal from the bloodstream, the 3H-heparin-coated balloons were pushed out of the protective sheath, and scintillation counting was performed. The quantity of 3H-heparin remaining on balloon surfaces after exposure to the intact circulation was compared with the two control balloons that were loaded with the same amount of 3H-heparin but not exposed to the bloodstream.
Quantitaton ofIntramural Heparin Delivery
To quantitatively evaluate 3H-heparin delivery to the arterial wall, angioplasty was performed in three pigs as described above using 10 balloons coated with 1000 U of 3H-heparin. Vessel segments were excised within 1 minute after balloon deflation, immersed in Solvable, and prepared for scintillation counting as described above.
Persistence of Intramural Heparin
To quantify the intramural persistence of heparin after delivery using a hydrogel-coated balloon, angioplasty was performed as described above in six pigs with 22 balloons coated with 1000 U of 3H-heparin. Vessel segments were excised at various time points up to 48 hours after angioplasty, immersed in Solvable, and prepared for scintillation counting as described above.
Effect of Local Heparin Delivery on Platelet Deposition
Nine anesthetized pigs were used to assess platelet deposition after heparin delivery. Platelet deposition was evaluated as described by Johnstone et all' using "'tIn-labeled platelets.
tttIn-tropolone was prepared by mixing 50 gtg of tropolone (Sigma) in normal saline solution with 0.5 mCi of`ttIn-chloride (New England Nuclear). Forty-three milliliters of whole blood was withdrawn into 7 mL of ACD saline (Mallinckrodt) and centrifuged at 180g for 15 minutes. Platelet-rich plasma (PRP) was removed and centrifuged at 1600g for 10 minutes. The platelet pellet then was resuspended with`ttIn-tropolone and 2 mL of ACD saline solution for 20 minutes and centrifuged for 10 minutes at 1600g. The pellet was resuspended in 4 mL of platelet-poor plasma (PPP), incubated for 5 minutes, and centrifuged for 10 minutes at 1600g. The labeled platelet pellet was resuspended in 5.5 mL of PPP and centrifuged at 100g for 10 minutes to remove any macroaggregates. The supernatant containing`ttIn-labeled platelets was then removed and reinjected intravenously.
Angioplasty was performed from 1 to 16 hours after reinjection of labeled platelets. Balloon angioplasty using balloons coated with 3000 U of heparin was performed in 14 iliac or carotid arteries. Balloon dilatation using the same-sized, saline-coated hydrogel balloon was performed in the contralateral vessel and served as the control. Four vessel pairs were not used for technical reasons. One hour after angioplasty the dilated arterial segment was excised, flushed gently with saline, stripped of adventitia, and counted in a gamma well counter. A symmetric 50-keV window centered around the 247-keV peak was used to quantitate "'tIn. Blood samples were obtained after angioplasty for determination of free and cell-bound`'In activity and for measurement of platelet counts and activated partial thromboplastin time (PTT).
Smooth Muscle Cell Proliferation Studies
To evaluate the effect of local heparin delivery on smooth muscle cell proliferation, vessel segments from seven pigs were examined by immunohistochemical staining for proliferating cell nuclear antigen (PCNA).12-14 Nine iliac or carotid vessels initially underwent angioplasty with heparin-coated balloons loaded with 3000 U of heparin. Contralateral vessels underwent angioplasty with same-size, saline-coated hydrogel balloons. After angioplasty, arteriotomy sites were repaired, the animal was allowed to waken and was returned to its cage. After 6 to 7 days, each animal was killed, and the carotid and iliac vessels were removed. Angioplasty was not performed on five vessel pairs for technical reasons.
Excised arterial segments were fixed for 12 hours in 10% buffered formalin. Four cross-sectional specimens then were taken from the site of angioplasty for quantitative immunohis staining, adjacent tissue sections were also stained with hematoxylin and eosin.
To determine the relative contributions of smooth muscle cells and other cells such as macrophages, selected sections were stained with monoclonal anti-smooth muscle actin antibody 1A418 (Sigma) and PC-10 using the histostain-DS kit for double labeling (Zymed Laboratories, Inc). Fast blue and aminoethylcarbazole, respectively, were used as chromogens.
Quantitation of PCNA expressed in the nuclei of proliferating cells was performed using the Cell Analysis-200 System by a single observer unaware of the vessel assignment to the control or heparin-treated group.13 Threshold levels of nuclear labeling (methyl green staining) were determined using control vessel sections labeled with nonimmune serum. Threshold levels of PCNA staining (DAB) were chosen to include all visually evident PCNA staining. Threshold levels were maintained constant for all sections of a given pair of vessels. Regions of interest (at 400-fold magnification) were selected to include four representative regions of the media from evenly spaced quadrants in four separate sections from each artery. The section of vessel demonstrating the most proliferation (PCNA staining) was used for all comparisons between heparin-treated and control vessels.
Data Analysis and Statistics
The presence of 3H-heparin detected either on the balloon surface or within the dilated vessel was expressed as a percentage of the 3H-heparin originally loaded onto the balloon. Platelet deposition was expressed as the calculated number of platelets deposited at the angioplasty site. The number of platelets deposited was calculated by multiplying the number of '"In cpm in the vessel by the number of platelets per milliliter of blood and dividing by the`"In cpm per milliliter of blood. The overall percentage reduction in platelet deposition was determined from the ratio of the difference between the average number of platelets deposited on the control vessels and the average number of platelets deposited on the heparintreated vessel divided by the average number on the control vessels. To calculate the average reduction in platelet deposition, the reduction in platelet deposition was calculated for each of the vessel pairs individually, and these percentages were then averaged. PCNA staining was expressed as the percentage of the total nuclear area staining with PC-10.
All Table 2 .)
Platelet Deposition
Platelet deposition was analyzed in a total of 14 vessel pairs, consisting of 6 iliac and 8 carotid pairs. In 7 vessel pairs, heparin delivery occurred before dilatation of the contralateral control vessel; in the remaining 7 pairs, the control vessel was dilated before heparin delivery in the contralateral artery. Balloon to artery diameter ratios were similar in the control vessels (1.40+0.11) and the heparin treated vessels (1.36±0.13, P=NS). (Table 4 ). The balloon to artery diameter ratio was 1.29±0.17 in the control vessels and 1.27±0.16 in the heparin-treated vessels (P=NS). In 8 of 9 vessel pairs, the heparin-treated angioplasty site demonstrated less medial cellular proliferation than the contralateral control vessel (Fig 2) . Overall, in control vessels, 12.7±9.7% of nuclear area demonstrated staining for PCNA compared with 8.5 ±7.1% of nuclear area in heparin-treated vessels (P=.03). Double labeling with both anti-PCNA and anti-smooth muscle actin antibody demonstrated the smooth muscle cell origin of proliferating cells within the media (Fig 3) .
Discussion
This study demonstrates, in a nonatherosclerotic porcine model, that hydrogel-coated balloons can deliver heparin intramurally at the time of balloon angioplasty. Although wash-off of heparin from the balloon surface and dissipation of intramural heparin occurred rapidly, small amounts of heparin delivered by this technique did persist at the angioplasty site for at least 48 hours. More importantly, locally delivered heparin decreased both early platelet deposition and PCNA-identified smooth muscle cell proliferation at the angioplasty site when compared with contralateral vessels that underwent similar injury.
Pharmacokinetic Studies
Despite inefficient delivery to the arterial wall and rapid disappearance of locally delivered heparin, small amounts of intramural heparin did persist for at least 48 hours. This persistence of heparin at the angioplasty site is consistent with previous evidence that heparin adheres to components of the damaged arterial wall.19-21 In vitro, heparin has been shown to bind to smooth muscle cells as well as to components of the extracellular matrix including fibronectin, collagen, von Willebrand factor, and basic fibroblast growth factor. In addition, heparin is taken up and internalized by smooth muscle cells. 22 Similarly, in an in vivo rat model, fluoresceinated heparin was deposited specifically at sites of arterial injury. 23 We have shown previously that fluorescein-labeled heparin can be detected for at least 24 hours after local delivery with hydrogel-coated balloons. 9 Only a small fraction of the amount of radioactive heparin that was originally loaded onto balloons could be detected intramurally. In part, this low efficiency of intramural delivery may have been related to heparin 
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W~~~~p tl wash-off from the balloon before heparin-hydrogel contact with the arterial wall. While heparin persistence in the vessel wall may be related to specific binding of heparin to wall components, it is also possible that heparin-binding sites have a nonsaturable component or were not fully saturated with the amount of 3H-heparin loaded on the balloon surface. If so, then loading larger amounts of heparin would result in a larger amount of heparin in the wall and possibly more pronounced effects on platelet deposition and smooth muscle cell proliferation.
Platelet Deposition
Heparin inhibits coagulation by accelerating the action of antithrombin III. However, in addition to inhibiting circulating coagulation factors, heparin has also been shown to have local anticoagulant effects at sites of arterial injury. As 33 The mechanism by which heparin inhibits smooth muscle cell replication is currently under investigation. In part, the effect of heparin may be secondary to decreasing platelet adherence and preventing the activation of smooth muscle cells in response to thrombus formation. In addition, heparin has been shown to displace basic fibroblast growth factor, a potent stimulator of smooth muscle cell migration and proliferation, from the arterial wall. 34 Achieving While this study demonstrated an extremely rapid wash-off of heparin from the hydrogel balloon surface, this problem was overcome by rapid deployment and inflation of the balloon. In addition, protection of the balloon surface with a protective sleeve prevented this rapid wash-off. Measures to decrease drug loss will need to be addressed in the clinical application of local hydrogel balloon delivery.
Study Limitations
In this study, both platelet deposition and smooth muscle cell proliferation were each evaluated at only a single time point after balloon injury. Previous studies have demonstrated that the platelet response to vessel injury is self-limited and that platelet deposition is maximal early after vessel injury and then falls off rapidly.47 '48 The decreased platelet deposition observed in this study was noted at 1 hour after heparin delivery, at a time when only a small fraction of the heparin remained in the wall. It is therefore possible that early platelet aggregation immediately after balloon injury is partially inhibited by local heparin, resulting cumulatively in less platelets at the angioplasty site at later times. We have not addressed, however, whether there is a later convergence or even rebound of platelet deposition.
Similarly, there is evidence that smooth muscle cell proliferation is a self-limited process with maximal proliferation occurring within the first weekl2'3049 and that critical mediators of proliferation such as oncogenes are triggered with self-limited expression early after injury.5051 While a reduction in smooth muscle cell proliferation was found in this study at the time of expected peak proliferation, the subsequent course of smooth muscle cell proliferation was not evaluated. Conclusions This study demonstrates, in vivo, a physiological effect of a catheter-based local drug delivery system and supports the concept that local delivery may yield benefits in the absence of systemic effects. Localized heparin delivery using heparin-coated hydrogel balloons reduces platelet deposition after balloon-induced vascular injury and therefore may have further applications by decreasing intracoronary thrombus formation after balloon angioplasty. Equally important, local heparin delivery using this technique reduces smooth muscle cell replication and may have significant effects on chronic restenosis.
